Navigation Links
ViroPharma Announces Presentation of Additional HCV-796 Data at,Meeting of The European Association for the Study of the Liver

- Phase 1b Combination Data Highlight Favorable Tolerability and Additive Antiviral Activity of HCV-796 -

EXTON, Pa., April 13, 2007 /PRNewswire-FirstCall/ -- ViroPharma Incorporated today announced additional data from a Phase 1b study of HCV- 796, a unique, orally dosed hepatitis C virus (HCV) polymerase inhibitor at the 42nd Annual Meeting of the European Association for the Study of the Liver (EASL). This meeting is being held in Barcelona, Spain. These data on the antiviral activity and tolerability of twice daily HCV-796 in combination with pegylated interferon alfa-2b (peg-IFN) elaborate on previously presented data. HCV-796 is currently undergoing Phase 2 evaluation and is being co-developed with Wyeth Pharmaceuticals, a division of Wyeth .

These Phase 1b combination data demonstrate the additive antiviral effects of HCV-796 across multiple genotypes of hepatitis C virus, in treatment-naïve adult subjects with chronic hepatitis C infection. HCV-796 dosed twice daily plus peg-IFN displays clinical antiviral activity that is greater than that of HCV-796 or peg-IFN alone across all dose cohorts and tested HCV genotypes. Final safety and tolerability data show that HCV-796 is generally well tolerated when added to peg-IFN. Adverse events were generally consistent with known effects of interferons. No dose-limiting toxicities were observed across the range of HCV-796 study doses.

"In this Phase 1b study, HCV-796 provided added antiviral activity to that of pegylated interferon across multiple HCV genotypes and did so largely without altering interferon's tolerability profile," commented Colin Broom, ViroPharma's chief scientific officer. "The adverse events observed in patients on combination therapy were typical of those seen in patients on pegylated interferon alone. The antiviral activity of HCV-796, its strong tolerability profile, and its lack of dose limiting toxicities encou
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
(Date:7/28/2014)... 2014   Stone & Magnanini LLP ... and fraud claims between the United States Department ... The settlement covers fraud in connection with the ... ablation of varicose veins for unapproved uses. ... history of representing whistleblowers in groundbreaking settlements, represented ...
(Date:7/28/2014)... CLEVELAND , July 28, 2014  Surgical ... new members to its Business Advisory Board. New ... Senior Vice President for Business Development and New ... (Jim) Fulton , former Senior Vice President and ... unit. Surgical Theater applies flight simulation technology to ...
(Date:7/28/2014)... , July 28, 2014 Southern ... Tipton , Ph.D., President and CEO of Southern ... Controlled Release Society (CRS) for the 2014-2015 term.  ... meeting on July 12 in Chicago ... countries.  The Controlled Release Society ...
Breaking Medicine Technology:Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 2Stone & Magnanini LLP Announces $520,000 Department of Justice False Claims Act Settlement With Vascular Solutions, Inc. 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 2Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 3Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 4Surgical Theater Names Former Given Imaging Ltd. and Philips Healthcare Executives to Business Advisory Board 5Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 2Arthur J. Tipton, Ph.D., Named President of Controlled Release Society 3
... Nov. 11, 2010 Applied Precision, a leader in life ... four of its revolutionary DeltaVisio n OMX® ... weeks. The Delta V ision ... than doubles the optical resolution of the traditional light microscope ...
... Reata Pharmaceuticals today announced that the company will present ... clinical trial of bardoxolone methyl in patients with ... The data will be presented in a late-breaking oral presentation ... Conference to be held November 16-21, 2010, in Denver, ...
Cached Medicine Technology:Applied Precision Installs a Record Four New DeltaVision OMX Super-Resolution Imaging Systems in Eight Weeks 2Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease 2Reata Pharmaceuticals to Present Data from Pivotal Phase 2b Trial in Type 2 Diabetics With Chronic Kidney Disease 3
(Date:7/28/2014)... An estimated 68,000 women and men ... and prostate cancers – an aggressive form of the ... other parts of the body, such as the lungs, ... University College of Medicine have developed a compound ... progression by blocking tumor cells from “re-seeding.” Their discovery ...
(Date:7/28/2014)... Randy Dotinga HealthDay ... Scientists know it takes humans just milliseconds to look at ... Now, a new study finds that certain facial features seem ... The shape and size of the mouth, for example, ... dimensions are keys to attractiveness. The study findings ...
(Date:7/28/2014)... treat severe chronic migraine headaches led to significant symptom ... patients treated at Massachusetts General Hospital (MGH). Physicians ... report that more than half of 35 patients treated ... headaches associated with compression of craniofacial nerves reported ... paper has received advance online publication in the journal ...
(Date:7/28/2014)... 2014 Thousands of DePuy Pinnacle hip ... individuals who were allegedly injured by a metal-on-metal version ... forward in U.S. District Court, Northern District of Texas, ... on July 18, 2014, U.S. District Judge Ed Kinkeade ... Plaintiffs’ Steering Committee that sought the deposition of a ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Glutamine is ... and it’s considered to be conditionally essential during times ... is an advanced recovery & Immune System Support. , ... glutamine your body produces, supplementing with additional glutamine may ... waste products in the body, digestion and immune system ...
Breaking Medicine News(10 mins):Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 2Health News:Drexel Scientists Develop Compound to Stop Spread of Metastatic Cancer Cells 3Health News:Facial Dimensions May Be Key to First Impressions 2Health News:Facial Dimensions May Be Key to First Impressions 3Health News:Non-endoscopic migraine surgery provides significant symptom relief 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit News: New Order Issued in Federal Pinnacle Hip Implant Litigation, Bernstein Liebhard LLP Reports 4Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 2Health News:Betancourt Nutrition Introduces Glutamine Plus with Sustamine® L-Alanyl-L-Glutamine 3
... be involved in decisions regarding quality of the donor ... a higher risk of failure, according to research by ... of patients would choose to remain on the waiting ... to the study,s lead author Michael L. Volk, M.D., ...
... (HealthDay News) -- ,The timing of an operation doesn,t affect ... study finds. For example, there,s no difference in death ... morning or on Monday instead of Friday, the researchers said. ... lead to a higher rate of safety problems when operations ...
... with obstructive sleep apnea are more likely to stick ... involved with their treatment, according to a team of ... airway collapses during sleep. It is the most common ... become more elevated in obese people. The first line ...
... Optimism is associated with higher grades for female students, but ... at Ben-Gurion University of the Negev in Israel assessed the ... 72 percent female) aged 20 to 28. The investigators ... grades than those who were less optimistic. However, high levels ...
... a chronic swelling condition common in breast cancer survivors, ... past, most people believed that exercise might induce or ... researchers say the benefits of exercise outweigh the risks ... Jane Armer, professor in the Sinclair School of Nursing, ...
... issue of Hepatology , a journal of the ... uncovered limitations in screening for primary liver cancer, also ... that, if given the choice during a clinical trial, ... of non-screening, therefore making a randomized study of HCC ...
Cached Medicine News:Health News:Transplant candidates seek best quality livers, even if it means waiting longer 2Health News:Time of Surgery Doesn't Influence Results, Study Says 2Health News:Innovative approaches help sleep apnea sufferers benefit from CPAP 2Health News:MU researchers recommend exercise for breast cancer survivors, lymphedema patients 2Health News:Studies of patients with cirrhosis uncover limitations in liver cancer screening 2
Irrigation pump for arthroscopy....
... DVD Burner captures still images and ... patient archives allows for multiple cases ... The unit provides software burned to ... playback and editing. Compatible with DICOM ...
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements....
The A3 3-Chip Camera includes digital processing, seamless autoshutter, industry-leading reliability, white balance with memory function, ease of operation, and a 2 year warranty....
Medicine Products: